Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-20093 or SHR2554 plus novel endocrine therapy in metastatic prostate cancer
CTR20254456Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Dec 2025
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of risvutatug rezetecan, zeprumetostat, tissue-plasminogen activator, darolutamide, enzalutamide in prostate cancer (PCa), sponsored by Hengrui Therapeutics. Started Dec 2025; status: active.
02
Drugs
risvutatug rezetecanzeprumetostattissue-plasminogen activatordarolutamideenzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20254456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254456.